Is AnaptysBio (ANAB) One of the Best Performing Healthcare Stocks so Far in 2026?

AnaptysBio, Inc. (NASDAQ:ANAB) is one of the best performing healthcare stocks so far in 2026. Piper Sandler cut the price target on AnaptysBio, Inc. (NASDAQ:ANAB) to $93 from $95 on May 4, reaffirming an Overweight rating on the shares. The firm stated that the company announced in April 2026 the completion of the First Tracks Biotherapeutics (TRAX) spinoff, and thus now operates as a royalty management company, exclusively responsible for its financial collaborations with GSK and Vanda Pharmaceuticals.

Is AnaptysBio, Inc. (ANAB) the Unstoppable Growth Stock to Invest in Now?

Ultimately, Piper Sandler stated that it believes the separation makes sense, as it effectively works to protect and optimize the value of the royalty business. This is fundamentally distinct from the biopharma development company.

In another development, AnaptysBio, Inc. (NASDAQ:ANAB) announced on April 24 that the Delaware Chancery Court has dismissed Tesaro’s anticipatory breach of contract claim against the company, with the ruling agreeing with Anaptys’ position that it has never repudiated the Collaboration and Exclusive License Agreement with Tesaro regarding the development and commercialization of Jemperli. Tesaro is a subsidiary of GSK.

AnaptysBio, Inc. (NASDAQ:ANAB) is a clinical-stage biotechnology company that exclusively manages the financial collaborations from Jemperli with GSK and imsidolimab with Vanda.

While we acknowledge the risk and potential of ANAB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ANAB and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.